Suppr超能文献

二甲双胍通过靶向肝星状细胞中的呼吸链复合体I诱导线粒体分裂并降低能量代谢,从而逆转肝纤维化。

Metformin induces mitochondrial fission and reduces energy metabolism by targeting respiratory chain complex I in hepatic stellate cells to reverse liver fibrosis.

作者信息

Su Ying, Hou Chenjian, Wang Meili, Ren Kehan, Zhou Danmei, Liu Xiaoli, Zhao Shanyu, Liu Xiuping

机构信息

Department of Pathology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.

Department of Pathology, Shanghai Fifth People's Hospital, Fudan University, Shanghai 200240, China.

出版信息

Int J Biochem Cell Biol. 2023 Apr;157:106375. doi: 10.1016/j.biocel.2023.106375. Epub 2023 Jan 27.

Abstract

The activation and proliferation of hepatic stellate cells (HSCs) are critical processes for the treatment of liver fibrosis. It is necessary to identify effective drugs for the treatment of liver fibrosis and elucidate their mechanisms of action. Metformin can inhibit HSCs; however, no systematic studies demonstrating the effects of metformin on mitochondria in HSCs have been reported. This study demonstrated that metformin induces mitochondrial fission by phosphorylating AMPK/DRP1 (S616) in HSCs to decrease the expression of α-SMA and collagen. Additionally, metformin repressed the total ATP production rate, especially the production rate of ATP produced through mitochondrial oxidative phosphorylation, by inhibiting the enzymatic activity of complex I. Further analysis revealed that metformin strongly constrained the transcription of mitochondrial genes (ND1-ND6 and ND4L) that encode the core subunits of respiratory chain I. Upregulation of the mRNA expression of HK2 and GLUT1 slightly enhanced glycolysis. Additionally, metformin increased mitochondrial DNA (mtDNA) copy number to suppress the proliferation and activation of HSCs, indicating that mtDNA copy number can alter the fate of HSCs. In conclusion, metformin can induce mitochondrial fragmentation and low-level energy metabolism in HSCs, thereby suppressing HSCs activation and proliferation to reverse liver fibrosis.

摘要

肝星状细胞(HSCs)的激活和增殖是肝纤维化治疗的关键过程。确定治疗肝纤维化的有效药物并阐明其作用机制很有必要。二甲双胍可以抑制肝星状细胞;然而,尚未有系统研究报道二甲双胍对肝星状细胞中线粒体的影响。本研究表明,二甲双胍通过使肝星状细胞中的AMPK/DRP1(S616)磷酸化来诱导线粒体分裂,从而降低α-SMA和胶原蛋白的表达。此外,二甲双胍通过抑制复合体I的酶活性来抑制总ATP产生速率,尤其是通过线粒体氧化磷酸化产生的ATP的产生速率。进一步分析表明,二甲双胍强烈抑制编码呼吸链I核心亚基的线粒体基因(ND1-ND6和ND4L)的转录。HK2和GLUT1的mRNA表达上调略微增强了糖酵解。此外,二甲双胍增加线粒体DNA(mtDNA)拷贝数,以抑制肝星状细胞的增殖和激活,表明mtDNA拷贝数可以改变肝星状细胞的命运。总之,二甲双胍可以诱导线粒体碎片化和肝星状细胞中的低水平能量代谢,从而抑制肝星状细胞的激活和增殖,逆转肝纤维化。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验